Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases
- 5 July 2018
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 182 (4) , 542-553
Abstract
Summary: Histone deacetylase inhibitors (HDACi) had emerged as promising drugs in leukaemia, but their toxicity due to lack of specificity limited their use. Therefore, there is a need to elucidate the role of HDACs in specific settings. The study of HDAC expression in childhood leukaemia could help to choose more specific HDACi for selected candidates in a personalized approach. We analysed HDAC1‐11, SIRT1, SIRT7, MEF2C and MEF2D mRNA expression in 211 paediatric patients diagnosed with acute leukaemia. There was a global overexpression of HDACs, while specific HDACs correlated with clinical and biological features, and some even predicted outcome. Thus, some HDAC and MEF2C profiles probably reflected the lineage and the maturation of the blasts and some profiles identified specific oncogenic pathways active in the leukaemic cells. Specifically, we identified a distinctive signature for patients with KMT2A (MLL) rearrangement, with high HDAC9 and MEF2D expression, regardless of age, KMT2A partner and lineage. Moreover, we observed an adverse prognostic value of HDAC9 overexpression, regardless of KMT2A rearrangement. Our results provide useful knowledge on the complex picture of HDAC expression in childhood leukaemia and support the directed use of specific HDACi to selected paediatric patients with acute leukaemia.Keywords
Funding Information
- European Regional Development Fund
This publication has 52 references indexed in Scilit:
- Survival and cure trends for European children, adolescents and young adults diagnosed with acute lymphoblastic leukemia from 1982 to 2002Haematologica, 2013
- Differential mRNA Expression Levels of Human Histone-Modifying Enzymes in Normal Karyotype B Cell Pediatric Acute Lymphoblastic LeukemiaInternational Journal of Molecular Sciences, 2013
- The genetic basis of early T-cell precursor acute lymphoblastic leukaemiaNature, 2012
- Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemiaLeukemia, 2011
- Clinical Toxicities of Histone Deacetylase InhibitorsPharmaceuticals, 2010
- Expression Levels of Histone Deacetylases Determine the Cell Fate of Hematopoietic ProgenitorsJournal of Biological Chemistry, 2009
- Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemiaThe Lancet Oncology, 2009
- The many roles of histone deacetylases in development and physiology: implications for disease and therapyNature Reviews Genetics, 2009
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006